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1. Introduction 
Epilepsia partialis continua (EPC) resulting from localized encephalitis was first described 
by Kozhevnikov and Brun in 1895 in patients suffering from Russian spring-summer 
encephalitis. (Bien et al., 2005b) In 1958, Rasmussen described a syndrome of focal seizures 
due to chronic localized encephalitis in three cases. The heterogeneity of this syndrome was 
demonstrated by Oguni in a description of 48 cases in 1991 among which 80% had focal 
motor seizures of which 50% were continuous.(Oguni et al., 1991)  The syndrome occurred 
predominantly in children who had hemiparesis and cortical signs.(Oguni et al., 1991) Even 
though a diagnostic criteria has been proposed(Bien et al., 2005b), the aetio-pathogenesis 
remains unresolved. 
Rasmussen’s encephalitis (RE) is a rare neurological disease of childhood characterized by 
unilateral hemispheric atrophy, focal intractable seizures, and progressive neurological 
deficits. The affected brain tissue shows a chronic inflammatory histopathology and an 
autoimmune reaction is suspected. Therapeutic strategies include anticonvulsants, 
immunomodulation and surgery. (Bien et al., 2005b) This review covers the natural history, 
aetiopathogenesis, clinical features, diagnosis, and treatment of RE. 
2. RE by Theodore Rasmussen 
Rasmussen et al presented a clinico-pathologic report of three children suffering from a 
chronic illness, producing focal seizures and gradually producing severe damage to one 
cerebral hemisphere.(Rasmussen et al., 1958) Occasional specimens of scarred, atrophic 
brain removed for the treatment of focal cerebral seizures at the Montreal Neurological 
Institute showed striking perivascular collections of round cells, particularly in less severely 
damaged areas of the specimens. Rasmussen observed that in the past this perivascular 
cuffing was attributed to the effect on the brain of recurring seizures. He inferred, however, 
that this was a rather unsatisfactory explanation since the great majority of surgical 
specimens removed from patients with equally frequent focal seizures did not show this 
change.(Rasmussen et al., 1958) He suggested that this microscopic picture may indicate the 
presence of an unsuspected, more or less localized, chronic encephalitis that had smoldered 
along over a period of years.(Rasmussen et al., 1958)  
He opined that suggestions for therapy in the active phase of the disease, when it might be 
possible to prevent destruction of brain tissue, must await determination of etiologic factors. 
(Rasmussen et al., 1958) 
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Rasmussen speculated regarding the ability of some dormant viruses in the nervous system 
to be pertinent to the problem. He reasoned that localization of the lesions and their 
character are more consistent with viral encephalitis than with postinfectious perivenous 
encephalitis or with allergic encephalitis. He concluded that the histological appearance in 
each instance suggested chronic focal encephalitis of unknown cause which manifested with 
focal epilepsy.(Rasmussen et al., 1958) 
3. Aetio-pathogenesis and pathology of RE 
RE is a rare disease that should be envisaged as sporadic, since there is no evidence for a 
genetic component. There is, at present, no conclusive evidence why and how RE starts.  
3.1 Is RE an epileptic encephalopathy? 
In analogy to other conditions of childhood epilepsies with progressive neurological 
deterioration, it has been suggested that in RE, the epileptic activity itself may contribute to 
the functional decline.(Bien et al., 2005b) This is because focal motor deficit usually follows 
the onset of epilepsy and its severity seems to mirror the intensity of the seizure 
activity(Bien et al., 2005b; Chinchilla et al., 1994). Steroids given early in the course of the 
disease are able to reduce the severity of the deficit, when seizure activity is brought under 
control. The response to steroids may suggest that an inflammatory process underlies the 
manifestation with seizures and neurological deficit. Because for any inflammatory process, 
the immune effector cells or antibodies originate from the blood stream, the encephalitis is 
expected to be bilateral. Thus focal epilepsy has been postulated as the reason for the 
unilaterality of the encephalitis.(Bien et al., 2005b)  It has been suggested that focal seizures 
may damage the blood brain barrier allowing autoantibodies to cross the it thus causing 
unilateral brain damage.(Bien et al., 2005b)  
However, while seizures may lead to reversible Todd’s palsy probably due to neuronal 
exhaustion, there is no conclusive evidence yet that seizures on their own cause or precede 
encephalitis.(Rasmussen et al., 1958)  Rasmussen reiterated that the great majority of 
surgical specimens removed from patients with equally frequent focal seizures did not show 
features of focal encephalitis.(Rasmussen et al., 1958) Furthermore, unilaterality is not a 
constant finding in RE, and the progressive atrophy and epileptiform processes may 
progressively involve the other hemisphere.(Bien et al., 2005b) The fact that the seizure is 
originally focal could not be the basis for focal encephalitis. Rather focal seizures could be a 
manifestation of focal encephalitis. The effect cannot precede the cause. Therefore 
asymmetry of the pathogenic process may be responsible for focal seizures and focal 
neurological deficits. This is corroborated by reports of cases with hemiparesis and focal 
encephalitis preceding seizures.(Korn-Lubetzki et al., 2004) 
The factors responsible for the asymmetry remain unravelled. Nevertheless, the evidence for 
immunologic mechanisms is growing although the antigenic stimulus remains obscure.  
3.2 Role of CD-8 cells 
Unilateral encephalitis, an intriguing feature of RE, distinguishes it from any other 
inflammatory disease of the CNS. Histopathological findings in RE comprise lymphocytic 
infiltrates, microglial nodules, neuronal and astrocytic loss, and gliosis of the affected 
hemisphere.(Farrell et al., 1992; Robitaille, 1991) Destruction of neurons and astrocytes by 
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cytotoxic CD8 T cells has been proposed as a pathogenic mechanism underlying RE. 
(Schwab et al., 2009) 
Active brain inflammatory lesions contain large numbers of T lymphocytes, which are 
recruited early within the lesions suggesting that a T cell dependent immune response 
contributes to the onset and evolution of the disease(Farrell et al., 1992; Schwab et al., 2009). 
Moreover, the histopathological observation of granzyme B-containing CD8+ T cells in 
direct apposition to MHC class I positive neurons raised the hypothesis of a CD8+ T cells-
mediated neuronal attack as a key pathogenetic mechanism underlying RE. (Bien et al., 
2005b; Bien et al., 2002a; Bien et al., 2002c; Bien et al., 2005a; Schwab et al., 2009) Apart from 
neuronal cell death, CD8 cells may also be responsible for the degeneration of astrocytes 
found in RE lesions. (Bauer et al., 2002; Bauer et al., 2007)  
The antigens of these brain-infiltrating lymphocytes are still unknown. It is not even clear 
yet, whether the CNS-directed T-cell response (TCR) is focused towards particular antigens. 
Experimentally, this could be proven by demonstrating that individual clones are expanded 
in the tissue.(Bien et al., 2005b)  
In a longitudinal analysis of TCR in RE, severe perturbations of the TCR repertoire were 
found in brain infiltrates from all specimens, while clonal expansions, as evidenced by 
peripheral blood analysis, belonged to the CD8+ T-cell subset. In line with previous 
findings, histochemical analysis of the brain lesions showed Vb specific T cells containing 
the cytotoxic molecule granzyme B and lying in close appositions to NeuN+ neurons and 
GFAP+ astrocytes.(Bauer et al., 2002; Bauer et al., 2007; Bien et al., 2002b; Bien et al., 2002a; 
Bien et al., 2005a) Analysis of corresponding CNS/blood specimens revealed overlapping 
but also CNS-restricted expansions of certain TCR clonotypes suggesting expansions of T 
cells within the target organ itself. (Bauer et al., 2002; Bauer et al., 2007; Bien et al., 2002b; 
Bien et al., 2002a; Bien et al., 2005a) 
Longitudinal analysis of peripheral blood samples demonstrated dominance but also 
longitudinal persistence of specific CD8 T-cell clones over time. The Vb/Jb usage, length of 
the CDR3, and biochemical characteristics of the CDR3 amino acids suggested high 
similarities putatively related to common driving antigen(s) without shared clones. In 
conclusion, the data strongly support the hypothesis of an antigen-driven MHC class-I 
restricted, CD8+ T cell-mediated attack against neurons and astrocytes in the CNS 
dominating the pathogenesis in RE in contrast to a random attraction of cells as part of a 
secondary immune response.(Schwab et al., 2009)  
This process may persist for at least 1 to 2 years. (Schwab et al., 2009) The long-term 
persistence (or re-occurrence) of putatively pathogenic T-cell clones despite therapy (or even 
immunoablation) may indicate an ongoing exposure of the immune system to the antigenic 
trigger. This trigger (autoantigen or virus) could very well reside within the CNS. The 
finding of identical TCR clones between the CNS and peripheral blood compartment in 
patients with matching CNS-blood samples is in line with this assumption. However, 
because this was a small-scale study, further research is required to validate the hypothesis. 
3.3 Glu-R3 autoantibodies 
Autoantibodies against glutamate receptors (GluR3 and NR2B), first reported in Rasmussen 
encephalitis, have been observed in other focal epilepsies, central nervous system ischemic 
infarcts, transient ischemic attacks, sporadic olivopontocerebellar atrophy, systemic lupus 
erythematosus, and paraneoplastic encephalopathies.(Pleasure, 2008) 
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Furthermore, the hypothesis of RE as a primarily antibody-driven attack against neuronal 
structures [e.g. the glutamate receptor GluR3 could not be confirmed in larger cohorts (Bien 
et al., 2005b). Thus the detection of glutamate receptor autoantibodies is not useful in the 
evaluation of Rasmussen encephalitis. (Pleasure, 2008)  
This does not exclude that other humoral mechanisms may contribute to the pathogenesis of 
RE. Future antibody research in RE will probably concentrate on detecting possibly pathogenic 
antibodies other than glutamate receptor antibodies.(Bien et al., 2005b; Pleasure, 2008) 
3.4 Pathological features 
The precise nature and sequence of the pathogenetically relevant processes remain 
controversial. It is unclear if a uniform process exists in all stages of the disease in all RE 
patients.(Bien et al., 2005b; Pleasure, 2008)  
The histopathological properties of RE have been described in several studies.(Bien et al., 
2005b; Bien et al., 2002b; Bien et al., 2002c) Using standard histochemical staining 
techniques, four stages corresponding to disease duration have been proposed. Group 1 
(earliest phase) is characterized by inflammation with numerous microglial nodules, with or 
without neuronophagia, perivascular round cells and glial scarring. Group 2 reveals several 
microglial nodules, cuffs of perivascular round cells, and at least one gyral segment of 
complete necrosis. Group 3 shows neuronal loss and gliosis with moderately abundant 
perivascular round cells and few microglial nodules. Finally, group 4 (last phase) displays 
no or few microglial nodules, neuronal loss and mild perivascular inflammation, combined 
with various degrees of gliosis and glial scarring. (Bien et al., 2005b; Bien et al., 2002b; Bien 
et al., 2002c; Robitaille, 1991)  
The round cell infiltrates in RE brains consist almost exclusively of T lymphocytes. Using a 
quantitative histopathological immunohistochemical approach, it has been demonstrated 
that densities of T cells, microglial nodules and activated astrocytes are inversely correlated 
with disease duration. Furthermore, the immunohistochemical observations showed that 
the majority of the T cells are CD8+ containing GrB+ granules. A proportion of them laid in 
apposition to neurons. These neurons were positive for MHC class I. A few neurons were 
found to die by apoptosis. These findings were interpreted as evidence for a cytotoxic T cell 
reaction against neurons. (Bien et al., 2005b; Bien et al., 2002b; Bien et al., 2002c; Robitaille, 
1991) 
Another diagnostically relevant observation was that <5% of the CD68+HLADR + cells had 
macrophage morphology (the remainder had microglial morphology). In addition, CD20+ 
cells (B cells) and CD138+ cells (plasma cells) are extremely rare and signs of 
immunoglobulin deposits or activated complement were not found. (Bien et al., 2005b; Bien 
et al., 2002b; Bien et al., 2002c) 
A viral aetiology was already suggested by Rasmussen based on the constituents of the 
immune reaction in the brains such as lymphocyte infiltration and microglial nodules 
(Rasmussen et al., 1958). The similarities of RE and Russian spring summer 
meningoencephalitis, which is caused by a flavivirus, further supported this 
hypothesis.(Bien et al., 2005b) However, so far all attempts to identify a pathogenic viral 
agent have been contradictory and inconclusive. Bien Inclusion bodies suggestive of a viral 
infection have not been observed in RE.(Bien et al., 2005b) 
Available data continue to suggest a T cell-led immune basis to the pathogenesis of RE. 
However, the antigenic basis is still obscure. Serial examinations in the early phase of the 
disease might be important in identifying this group of patients, so that more detailed study 
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of possible etiologic factors might be made before the fire has burned out and only the 
scarred evidence of earlier damage remains. (Rasmussen et al., 1958) 
4. Clinical features 
4.1 Natural history and evolution 
Although reported cohorts of individuals with RE are not large, three stages have been 
proposed. (Bien et al., 2005b; Bien et al., 2002c; Bien et al., 2002d). The average age at 
presentation is 6 years of age. (Bien et al., 2005b; Bien et al., 2002c; Oguni et al., 1991) In 
about two-thirds of patients, RE  may commence in some patients with a non-specific 
‘prodromal stage’ manifesting with a relatively low seizure frequency and rarely mild 
hemiparesis with a median duration of 7.1 months (range: 0 months to 8.1 years).(Bien et al., 
2005b; Bien et al., 2002c; Bien et al., 2002d; Oguni et al., 1991) 
All patients enter an ‘acute stage’ of the disease characterized by frequent seizures, mostly 
simple partial motor seizures often in the form of epilepsia partialis continua (EPC). The 
neurological deterioration becomes manifest by progressive hemiparesis, hemianopia, 
cognitive deterioration and, if the dominant dominant hemisphere is affected, aphasia. (Bien 
et al., 2005b; Bien et al., 2002c; Oguni et al., 1991) The median duration of this stage is 8 
months (range 4–8 months).(Bien et al., 2005b; Bien et al., 2002c; Oguni et al., 1991) 
The final stage is the ‘residual stage’ with permanent and stable neurological deficits and 
still many seizures, although less frequent than in the acute stage. At this stage, not all the 
patients are hemiplegic.(Bien et al., 2005b; Bien et al., 2002c; Oguni et al., 1991)   
The wide time ranges for the duration of the disease stages indicate the high variability of 
severity and speed of the destructive process in different patients. For clinical monitoring of 
the progression, hemiparesis is the most useful marker as this feature is most consistently 
found, and it allows quantitative evaluation, even in children.(Bien et al., 2005b; Bien et al., 
2002c; Oguni et al., 1991) Assessment of degree of hemiparesis is best done in periods with 
low frequency of seizures, because it can be increased by additional transient postictal 
paresis in cases with motor seizures. In addition, periodic assessment of neuropsychological 
performance is recommended in order to detect cognitive decline, especially in cases 
without overt hemiparesis, such as those of temporal lobe origin. (Bien et al., 2005b; 
Hennessy et al., 2001) 
Monitoring can also be done using the hemispheric ratio on neuroimages. 
4.2 Characteristics of the seizures in RE 
Epilepsy in RE patients is characterized by the polymorphism of seizures in a given patient; 
the frequent occurrence of EPC; and the medical intractability of seizures, particularly of 
EPC.(Bien et al., 2005b) The different semiologies of seizures, often noted on longitudinal 
evaluation of patient records, is best explained as a ‘march (of the epileptic focus) across the 
hemisphere’. (Oguni et al., 1991) Supportive findings have been made by serial 
neuroimaging studies. However, apart from the rare cases of bilateral RE, all seizures 
originate in one hemisphere. (Bien et al., 2005b) 
Simple partial motor seizures involving one side of the body are the most common (77% of 
cases), followed by secondarily generalized tonic clonic seizures (42%), complex partial 
seizures (19% with automatisms and 31% with subsequent unilateral motor involvement), 
postural seizures probably originating in the supplementary motor region (24%) and 
somatosensory seizures (21%) (Oguni et al., 1991). EPC has been reported to occur in 56–92% 
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of patients at some time during their disease course EPC was originally described in Russian 
adults suffering from Russian springsummer encephalitis and has subsequently caused 
extensive discussions regarding its nature and origin. EPC is most commonly viewed as 
cortical and epileptic.  
4.3 Possible variants of RE 
In contrast to the classical features mentioned above, certain clinical variants of RE exist. 
4.3.1 RE with delayed seizure onset 
Patients with progressive hemiparesis and biopsy evidence of RE followed by unilaterally 
generated seizures only after several months have been reported. (Korn-Lubetzki et al., 
2004). 
4.3.2 RE with movement disorder 
Unilateral basal ganglia involvement (usually the caudate nucleus) has been reported to 
present with features of hemidystonia and hemiathetosis in addition to EPC. (Bhatjiwale et 
al., 1998; Bien et al., 2005b)   
4.3.3 Localised form   
Mild and non-progressive phenotypes of the disease have been reported with childhood or 
late-onset chronic focal encephalitis, dominated by partial seizures with mild focal motor 
deficit and choreo-dystonic movements. (Gambardella et al., 2008)  
4.3.4 Bilateral cases 
The term ‘bilateral RE’ should be reserved for cases with inflammatory lesions in both 
hemispheres. Although several clinical and electrophysiological features have suggested 
bilateral cerebral invlovelment in many cases (e.g. secondary spread of focal seizures to the 
contralateral side, interictal epileptiform abnormalities on the contralateral side, or mild 
contralateral atrophy). (Andermann et al., 2006; Bien et al., 2005b; Hart, 2004) True bilateral  
RE is very rare.  
There is no evidence for an inherent tendency of RE to spread to the contralateral side after 
longstanding disease. Furthermore with over 10 years follow-up: no case of RE initially 
cured by surgery from the epilepsy point of view exhibited delayed relapse on the 
contralateral side, even when the affected hemisphere was not removed but purely 
disconnected.(Bien et al., 2005b; Delalande et al., 2004) 
4.3.5 Late-onset RE 
Although RE is generally considered as a childhood disease, adolescent and adult patients 
have been described and may account for about 10% of all RE cases. (Bien et al., 2005b) The 
oldest patient reported so far was 58-years-old. (Hunter et al., 2006)  
While adult-onset Rasmussen's syndrome may mimic the early-onset form, symptoms often 
progress more slowly and the neurological defect is more variable. They appear to have a 
more protracted and milder clinical course with less residual functional deficits and lower 
degrees of hemiatrophy and more frequent occipital lobe seizure onset (Bien et al., 2005b; 
Hart et al., 1997), but identical histopathological as well as clinical, electrophysiological and 
neuroimaging findings.(Bien et al., 2005b)  
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Some atypical features may be noted such as bilateral hemispheric involvement or a picture 
of temporal lobe epilepsy or the presence of movement disorders at the beginning of the 
disease. Surgical hemispheric disconnection that appears the most effective treatment in 
children to improve seizure control is not indicated in adults for evident functional reasons. 
Based on recent pathogenic concepts, different medical treatments may be proposed. Large 
multicentre controlled studies are mandatory to define a clear medical therapeutic strategy 
in these cases of adult-onset.(Jaillon-Riviere et al., 2007)  
4.3.6 RE with unilateral brainstem encephalitis  
The case of an adult woman with Rasmussen encephalitis with brainstem involvement 
responsive to immunosupression is reported. (Quesada et al., 2007) 
4.3.7 RE with neurological comorbidity 
Cases with double cranial pathology (RE plus low grade tumour, cortical dysplasia, 
tuberous sclerosis, vascular abnormalities or old ischaemic lesions) have been 
described.(Bien et al., 2005b; Hart et al., 1998) In the Montreal series, about 10% of cases had 
double pathology. (Bien et al., 2005b; Hart et al., 1998) The diagnosis of dual pathology was 
suspected based on MRI findings and confirmed by histopathology (biopsy or resective 
epilepsy surgery). 
5. Investigations 
5.1 EEG features  
As early as 4 months after disease onset, EEG shows polymorphic delta waves over the 
affected hemisphere, mainly in a temporal and central location (Figure 1).(Bien et al., 2005b; 
Hart et al., 1998; Owolabi et al., 2008) This may be accompanied by epileptiform 
abnormalities, which may evolve into (subclinical) ictal EEG patterns. During the disease 
course, in most cases, contralateral asynchronous slow waves and epileptiform discharges 
occur. However, ictal patterns are rarely recorded from contralateral electrodes. As in other 
conditions, EPC in RE is not always accompanied by rhythmic EEG discharges on surface 
EEG.(Bien et al., 2005b) 
Thus EEG may contribute to the tentative diagnosis of RE already in early disease stages. 
The following unihemispheric findings strongly suggest RE: impairment of background 
activity and sleep spindles; focal slow activity; multifocal ictal discharges; and subclinical 
ictal discharges. In cases with the secure diagnosis of RE, the documentation of an 
independent contralateral seizure onset may raise the suspicion of bilateral disease.(Bien et 
al., 2005b) 
5.2 Radiological features 
5.2.1 CT and MRI  
Rarely, CT and MRI may be normal on very early scans. (Bien et al., 2005b; Bien et al., 2002c; 
Bien et al., 2002d) Within the first 4 months after disease onset, the majority of patients 
exhibit unilateral enlargement of the inner and outer CSF compartments, most accentuated 
in the insular and periinsular regions, with increased cortical or subcortical (or both) T2 (and 
FLAIR) signal (Figures 2 and 3). In addition, in most cases, there is atrophy of the ipsilateral 
head of the caudate nucleus. 
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Fig. 1. EEG features in a young girl with RE (Owolabi et al., 2008) 
Theta and delta waves on the left hemisphere with epileptiform sharp and slow wave 
complexes and phase reversal pattern. These features predominated in the temporo-central 
region. No evidence of secondary generalization. 
 
 
    
Fig. 2. Cranial CT scan 
Isolated left hemispheric atrophy with non-enhancing hypodense lesions. 
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T1 W sagittal MRI (right)                                          T2 W  MRI 
  
FLAIR sequence                                              T1 W gd-DTPA 
Fig. 3. Brain MRI  T1W and T2W transverse and sagittal images as well as FLAIR transverse 
and coronal images were obtained. The images show left unilateral cerebral atrophy worse 
at the frontal occipital and perisinsular regions. There is associated ipsilateral dilatation of 
the lateral ventricle and widening of the cerebral sulci. The T2W images show diffuse 
increased signal intensity in the cortical and subcortical white matter which are of decreased 
signal on T1W images. The FLAIR images also show increased signal changes in the frontal 
and occipital white matter on the left. 
The right cerebral hemisphere, brainstem and cerebellum are all within normal limits. 
The post gadolinium images show no evidence of enhancement. 
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A few patients transiently show focal cortical swelling on early scans. Subsequently, a 
spread of signal changes and atrophy within the affected hemispheres is observed. 
In areas with increased MRI signal, the intensity of inflammation as measured by number of 
T cells, microglial nodules and GFAP+ astrocytes is increased compared with more 
chronically affected areas with advanced atrophy and no more signal increase.(Bien et al., 
2005b; Bien et al., 2002c; Bien et al., 2002d) Using a quantitative approach (calculation of the 
‘hemispheric ratio’, i.e. the ratio affected/unaffected hemisphere on planimetry of axial and 
coronal slices including the Sylvian fissure) to assess the temporal evolution of hemiatrophy, 
most of the tissue loss occurs during the first 12 months after onset of the acute disease 
stage.(Bien et al., 2005b; Bien et al., 2002c; Bien et al., 2002d) However, it may, in some cases, 
go on for several years.(Bien et al., 2005b; Bien et al., 2002c; Bien et al., 2002d) 
In a series of immunotreated RE patients, volumetric assessment of serial MRIs during early 
disease stages revealed a median tissue loss of 29.9 cm3 per year in the affected and of 6.8 
cm3 in the unaffected hemispheres.(Larionov et al., 2005) Gadolinium enhancement is very 
rare in RE.(Bien et al., 2005b; Bien et al., 2002c)  
5.2.2 PET studies 
PET studies, almost exclusively performed using the tracer fluorodeoxyglucose (FDG), show 
abnormalities confined to the affected hemisphere. In most cases, large areas of 
hypometabolism are observed; in the remainder (mostly ‘ictal’ studies in patients with 
ongoing EPC), additional areas of focal hypermetabolism are found.(Bien et al., 2005b)  
FDG-PET changes in early stages (disease duration up to 1 year) are confined to 
frontotemporal areas. In later stages, abnormalities also affect posterior cortical regions. 
(Bien et al., 2005b) 
One case study suggested that FDG-PET-hypermetabolism correlates with ongoing electrical 
seizure activity whereas methionin- PET-hypermetabolism indicates areas of inflammation, 
but this needs to be confirmed in larger patients group.(Bien et al., 2005b) It has been 
proposed that PET might guide brain biopsy in cases with inconclusive or normal MRI 
findings, especially in early stages. 
5.2.3 Single photon emission computed tomography (SPECT) 
With interictal and ictal SPECT, the same type of results and conclusions have been reached 
as with PET (Bien et al., 2005b) 
5.2.4 Magnetic resonance spectroscopy (MRS) 
Magnetic resonance spectroscopy (MRS) studies consistently showed decreased N-acetyl-
aspartate (NAA) levels and increased (or normal) choline (cho) peaks resulting in a 
decreased NAA/cho-ratio suggestive of neuronal loss or dysfunction.(Bien et al., 2005b) 
Partly observed increased lactate peaks seemed to be associated with the presence of EPC.  
The present studies do not provide evidence for RE-specific MRS abnormalities. 
In conclusion, PET, SPECT and MRS techniques are not suitable for defining  
the inflammatory nature of the condition. They may, however, help in confirming  
the unihemispheric nature in suspected early RE findings. (Bien et al., 2005b) Simultaneous 
fMRI and EEG recording may be useful in planning surgery. (Cuspineda Bravo et al.,  
2010) 
www.intechopen.com
 
Rasmussen’s Encephalitis: An Overview 
 
245 
5.3 Laboratory features  
No laboratory test is available to positively support the diagnosis of RE. The largest series of 
CSF tests has been reported by the Montreal group. In about half of the examinations, cell 
counts and protein levels were in the normal range. In the remainder, elevated cell counts 
(16–70 cells/ml, predominantly lymphocytes), and increased protein content (50–100 
mg/dl) or a first or midzone elevation of the colloidal gold curve were observed. In only 
15% of the abnormal CSF tests, were all three parameters were abnormal.(Bien et al., 2005b) 
Oligoclonal bands are an inconsistent finding ranging from 0 to 67% in some small 
series.(Bien et al., 2005b)  
GluR3 antibodies in serum (and CSF alike) do not discriminate between RE and 
noninflammatory epilepsy.(Bien et al., 2005b) Moreover, the presence or absence of GluR3 
antibodies does not allow specific pathogenic clues in a given patient and should not be 
used to select or exclude a specific treatment.  
Therefore, CSF standard tests are not suitable to exclude or confirm the diagnosis of RE. 
Serological CSF tests are usually applied to rule out a CNS infection by known neurotropic 
agents.  
5.4 Brain biopsy 
Brain biopsy is not required in all RE cases because other criteria can be sufficient to 
diagnose the condition. In ‘burnt out’ cases, brain biopsy may give nonspecific results and 
not lead to initiation of immunomodulatory treatment.(Bien et al., 2005b) In cases not 
fulfilling the noninvasive diagnostic criteria as well as in less common RE forms, brain 
biopsy can contribute considerably to diagnostic certainty.(Bien et al., 2005b) 
However, false negative results may be obtained in a small stereotactic needle biopsy 
because normal and abnormal tissue elements may be located in very close apposition.(Bien 
et al., 2005b) Therefore, if there are no contraindications, an open biopsy comprising 
meninges, grey and white matter is preferable. If, in suspicious cases, histology does not 
clearly show lymphocytic inflammation and microglial (nodular) activation, evaluation of 
serial sections may be necessary. Biopsy should be taken from a non-eloquent area where 
there is increased T2/FLAIR signal on MRI or abnormal findings in PET or SPECT. (Bien et 
al., 2005b) 
A gradient of inflammatory intensity from frontotemporal to occipital areas, especially in 
early cases, has been observed. Therefore, frontal or temporal biopsies are generally 
preferable. Cases with predominant parietal or occipital involvement, however, exist.(Bien 
et al., 2005b) 
True histopathological differential diagnoses to RE are not as numerous as sometimes 
assumed. Chronic viral encephalitides, paraneoplastic encephalitis  and nonparaneoplastic 
limbic encephalitis(Bien et al., 2005b) need to be considered. If the results of brain biopsy are 
inconclusive, further clinical and MRI follow-up studies (e.g. every 6 months) are required 
to clarify the nature of the disease. 
6. Diagnostic criteria 
A diagnostic criteria is proposed by the European Consensus statement (Table 1). RE can be 
diagnosed if either all three criteria of Part A or two out of three criteria of Part B are 
present.(Bien et al., 2005b) 
www.intechopen.com
 
Pathogenesis of Encephalitis 
 
246 
RE can be diagnosed if either all three criteria of Part A or two out of three criteria of Part 
B are present. Check first for the features of Part A. Then, if these are not fulfilled, of Part 
B. In addition: If no biopsy is performed, MRI with administration of gadolinium and 
cranial CT needs to be performed to document the absence of gadolinium enhancement 
and calcifications to exclude the differential diagnosis of a unihemispheric vasculitis . 
Part A: 
1. Clinical Focal seizures (with or without Epilepsia partialis continua) and Unilateral 
cortical deficit(s) 
2. EEG Unihemispheric slowing with or without epileptiform activity and Unilateral 
seizure onset 
3. MRI Unihemispheric focal cortical atrophy and at least one of the following: 
          Grey or white matter T2/FLAIR hyperintense signal 
           Hyperintense signal or atrophy of the ipsilateral caudate head 
Part B: 
1. Clinical Epilepsia partialis continua or Progressive* unilateral cortical deficit(s) 
2. MRI Progressive* unihemispheric focal cortical atrophy 
3. Histopathology T cell dominated encephalitis with activated microglial cells (typically, 
but not necessarily forming nodules) and reactive astrogliosis.  Numerous parenchymal 
macrophages, B cells or plasma cells or viral inclusion bodies exclude the diagnosis of RE. 
*‘Progressive’ means that at least two sequential clinical examinations or MRI studies are 
required to meet the respective criteria. To indicate clinical progression, each of these 
examinations must document a neurological deficit, and this must increase over time. To 
indicate progressive hemiatrophy, each of these MRIs must show hemiatrophy, and this 
must increase over time. 
Table 1. European Consensus Diagnostic Criteria for RE (2005)(Bien et al., 2005b)  
7. Differential diagnoses 
Differential diagnoses include unihemispheric epileptic syndromes, inflammatory diseases, 
metabolic or degenerative disorders. Unihemispheral epileptic syndromes include cortical 
dysplasia, hemimegalencephaly, tuberous sclerosis, 
Sturge-Weber-syndrome, stroke, and hemiconvulsion-hemiplegia-epilepsy-syndrome. (Bien 
et al., 2005b)   
Inflammatory diseases such as cerebral vasculitis in systemic connective tissue disease and 
unihemispheric cerebral vasculitis usually present with typical serological features, 
calcification on brain CT and gadolinium enhacement on MRI. Subacute sclerosing 
panencephalitis presents with period discharges on EEG. 
Epilepsia partialis continua (EPC) due to metabolic disorders such as DM and hepatic 
encephalopathy can be diagnosed with blood tests.  Metabolic or degenerative progressive 
neurological diseases such as MELAS and other can be diagnosed by mitochondrial DNA 
genetic testing for mutations and muscle biopsy. 
8. Treatment 
The goals of treatment are to reduce inflammation, control seizures and reverse functional 
deficits (motor, sensory, cognitive, etc). Pharmacologic, immunotherapeutic, surgical and 
www.intechopen.com
 
Rasmussen’s Encephalitis: An Overview 
 
247 
rehabilitative techniques are used to achieve these goals. Rarity of the condition makes it 
difficult to conduct RCTs to compare treatment options.  
8.1 Pharmacological control of seizures 
Classical AEDs are more effective in the control of complex partial seizures and secondarily 
generalized seizures than EPC. (Bien et al., 2009a) No anticonvulsive mono- or combination-
therapy has been described to be superior to other regimens. There is no evidence that the 
new AEDs have higher efficacy than older AEDs. However, their improved tolerability and 
reduced potential for pharmacokinetic interactions may be of particular importance if long-
term immune-treatment is applied. (Bien et al., 2009a) 
Enzyme-inducing drugs reduce blood-levels of corticosteroids and tacrolimus; enzyme-
inhibiting drugs, on the other hand, confer the risk of tacrolimus intoxication and 
encephalopathy. Substances with high albumin bound fraction may be difficult to keep at a 
constant blood level if in parallel with plasma exchange.  As a general rule, number and 
dose of AEDs should be kept as low as possible, i.e., one should try to abolish secondarily 
generalized tonic clonic and, possibly, complex partial seizures; EPC, however, is almost 
never suppressed by AEDs and it provides little benefit to the patients if one tries to 
suppress this focal motor status epilepticus. In cases of localised EPC, botulinum toxin has 
been successfully injected. (Bien et al., 2009a) Epilepsy surgery and immunotherapy are also 
helpful in seizure control. 
8.2 Immunotherapy  
Immunotherapeutic interventions include corticosteroids, immunoglobulin, plasmapheresis, 
interferon, rituximab, and tacrolimus. 
8.2.1 Corticosteroids 
Prednisolone/prednisone started at high doses and slowly tapered down have been 
reported to have beneficial effects on seizures and neurological functions in several series, 
particularly when started early in the course of the disease.(Bien et al., 2009a) However, 
serious side effects partly necessitating steroid withdrawal have been noticed. These include 
fluid retention/Cushing’s syndrome in all patients and, in single cases, psychosis, 
behavioural abnormalities, septicaemia, osteoporosis, hypertension and candidiasis.(Bien et 
al., 2009a) Therefore, for long-term steroid therapy, it has been recommended to start with 
boluses of intravenous methylprednisolone (e.g. 400 mg/m2/day) or, in children, 20 
mg/kg/day and then to introduce 1–2 mg/kg/day oral prednisolone or prednisone. This 
dose should be slowly reduced, ideally to a dose below the threshold of Cushing’s 
syndrome. Short-term steroid bolus administration (dosing as above) has been found to be 
effective in blocking status epilepticus.(Bien et al., 2009a) 
8.2.2 Intravenous Immunoglobulin (IVIG) 
Good effects of IVIG on seizures and neurological functions were reported in some case 
studies and seriess where IVIG is recommended as the first-line immunotherapy. 
Furthermore, favourable responses of adult cases have lead to the proposal IVIG as first-line 
treatment especially in late-onset cases.(Bien et al., 2009a)  The recommended dosing scheme 
is to start with three to five consecutive infusions of 0.4 g/kg/day and to proceed with a 
monthly dose of 0.4–2.0 g/kg distributed over 1–5 consecutive days. Side effects of IVIG 
treatment are rare. 
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8.2.3 IVIG plus steroid  
In case of insufficient effect of IVIG, a combination of 0.4 g/kg/month IVIG plus 
corticosteroids (dosing as above) is recommended. (Bien et al., 2009a) 
8.2.4 Plasma exchange/plasmapharesis 
Plasma exchange cycles have been performed at a frequency of three to six single volume 
exchanges on consecutive or alternate days, repeated every 2 to 8 weeks. Selective periodic 
immuno-adsorption with protein A has been used as a long-term management with positive 
results in adolescent-adult onset patients. Both measures improved neurological function 
and seizure frequency in some patients during the weeks following the intervention that 
could be reinstituted by repeat treatment. However there is very limited experience with 
long term treatment in RE. (Bien et al., 2009a) Long-term immunotherapy is usually 
ineffective against seizures. 
8.2.5 Tacrolimus  
Tacrolimus is a T cell inhibiting immunosuppressant. In a small controlled trial,  the 
tacrolimus patients had a superior outcome regarding neurological function and 
progression rate of cerebral hemiatrophy on MRI, but no better seizure outcome. Their 
cognitive outcome was good.(Bien et al., 2004; Bien et al., 2009a) The results of a randomized 
prospective trial, comparing tacrolimus and IVIG are still being awaited.(Bien et al., 2004; 
Bien et al., 2009a) 
8.2.6 IFN-alpha 
Report of seizure control with the use of intraventicular interferon-alpha has been 
made.(Bien et al., 2009a; Dabbagh et al., 1997)  However it is an invasive measure and 
further trials are required to verify its efficacy and determine its role in RE therapy. 
8.2.7 Rituximab    
Rituximab is a chimeric monoclonal antibody against the protein CD20. Although CD20+ 
cells (B cells) are extremely rare, rituximab may in single cases be a viable treatment 
alternative; a formal trial is underway. (Bien et al., 2005b) 
8.3 Surgical treatment 
Surgical treatment is indicated in medically-refractory seizures. Options include anatomic 
hemispherectomy, functional hemispherectomy, perisylvian hemispherotomy, trans-sylvian 
hemispherotomy and central/vertical hemispherotomy.(Bien et al., 2005b; Bien et al., 2009b; 
Bien et al., 2009a; Terra-Bustamante et al., 2009) However, only hemispherectomy 
(anatomical or functional) is effective in RE.(Bien et al., 2005b; Bien et al., 2009b; Bien et al., 
2009a; Terra-Bustamante et al., 2009) 
The basic principle of the modern techniques is to replace resection by disconnection.  
Presurgical evaluation for hemispherectomy should be performed in all patients with 
pharmacoresistant and handicapping seizures due to RE. Some special considerations 
during this presurgical assessment arise from the fact that RE represents the rare case of an 
epilepsy due to acquired hemispheric brain damage. In RE, patients with disease onset >4 
years of age (when secondary language transfer is no longer highly likely) need to be 
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investigated with particular scrutiny to predict the post-HE functioning. (Bien et al., 2005b; 
Bien et al., 2009b; Bien et al., 2009a; Terra-Bustamante et al., 2009) 
The following steps are recommended in the pre-op work-up of RE patients: brain MRI and 
video-EEG-monitoring for registration of interictal and ictal activity and prediction of 
postoperative functional outcome by assessment of the actual language, motor, visual 
function (visual field) and  language dominance lateralization, usually by means of Wada 
testing.(Bien et al., 2005b; Bien et al., 2009b; Bien et al., 2009a; Terra-Bustamante et al., 2009) 
However, it is imperative to determine cerebral dominance by Wada test prior to 
surgery.(Bien et al., 2005b; Bien et al., 2009b; Bien et al., 2009a; Terra-Bustamante et al., 2009) 
Language functional MRI alone has not been shown to be sufficient due to limited 
comparability of the two hemispheres as well as the restricted ability of the patients to 
follow instructions.(Bien et al., 2005b; Bien et al., 2009b; Bien et al., 2009a; Terra-Bustamante 
et al., 2009) 
8.4 Rehabilitation  
Depending on the type of neurological deficits, different modalities of rehabilitation are 
employed to improve the health-related quality of life of the patient. This includes 
physiotherapy, vocational therapy, occupational therapy, speech and language therapy, and 
cognitive rehabilitation. Botulinum toxin A is useful in the management of localized 
refractory EPC. 
8.5 Choice of therapy for individual patients 
Anti-seizure effect of anti-epilepsy drugs is usually limited to secondarily generalized 
seizures and complex partial seizures whereas EPC is usually refractory. (Bien et al., 2005b; 
Bien et al., 2009a) Hemispherectomy in one of its modern variants offers a very high chance 
of seizure freedom, however at the price of irreversible loss of functions located in the 
affected hemisphere.(Bien et al., 2005b; Bien et al., 2009a; Terra-Bustamante et al., 2009) In a 
proportion of patients, long-term immunotherapy is able to prevent or slow down 
hemispheric tissue loss and the associated functional decline. It does, however, mostly not 
improve the epilepsy. Whereas for many patients unequivocal treatment proposals can be 
readily made, a dilemma may emerge in those with severe epilepsy but still preserved 
hemispheric function.(Bien et al., 2005b; Bien et al., 2009a; Terra-Bustamante et al., 2009) 
In the European consensus statement on RE, a therapeutic protocol(Bien et al., 2005b; Bien et 
al., 2009a) for any patient with the diagnosis of RE has been suggested.  
8.5.1 Mild or absent epilepsy, with progressed functional deficit 
A low dose AED therapy will usually suffice in these cases. If complete seizure freedom 
cannot be achieved but is a major goal of the patient, surgery can be offered.(Bien et al., 
2005b; Bien et al., 2009a) 
8.5.2 Handicapping epilepsy, and no findings predicting a relevant post-op 
deterioration 
Here, surgery is clearly the treatment of choice. The patient and his family needs to be 
informed about the general risks of the procedure.(Bien et al., 2005b; Bien et al., 2009a; Terra-
Bustamante et al., 2009) 
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8.5.3 Mild or absent epilepsy with limited neurological deficit 
If the patient is still in the acute disease stage, i.e., has recently experienced a functional 
decline, this is certainly the ideal situation for long-term immunotherapy. The epilepsy is no 
or only a minor problem, and the functional decline may be stopped or at least slowed 
down by the immunotherapy. If, however, the patient is already in the residual stage (i.e., 
no functional decline within the previous 6 months or so), initiation of immunotherapy is no 
longer recommended.(Bien et al., 2005b; Bien et al., 2009a) 
8.5.4 Handicapping epilepsy, but prediction of significant functional deterioration 
after surgery 
This is certainly the most problematic situation.(Bien et al., 2005b; Bien et al., 2009b; Bien et 
al., 2009a; Terra-Bustamante et al., 2009) Early institution of long-term immunotherapy is 
recommended to prevent functional decline. If seizures remain severe and disabling, 
additional ‘‘short-term/intense’’ immunotherapy should be tried (e.g., an i.v. pulse of 
several days of methylprednisolone at 20 mg/(kg day) in children or 500—1000 mg/day in 
adults, or plasma exchange, or IVIG). If no satisfying effect is achieved, this add-on 
immunotherapy should be discontinued, and the option of HE should be considered as 
discussed above. (Bien et al., 2005b; Bien et al., 2009a) 
The severity of each of the expected deficits after surgery should be weighed in relation to 
the severity of epilepsy.(Bien et al., 2005b; Bien et al., 2009a; Terra-Bustamante et al., 2009; 
Terra-Bustamante et al., 2007) This requires extensive and in-depth discussions with the 
patient and his family. Whereas the prediction of postoperative aphasia in a still 
communicable child (RE of the language dominant hemisphere) will usually preclude 
surgery, the perspective of a fixed dense hemiparesis with preserved walking abilities may 
be an acceptable price for seizure freedom. This is particularly clear in cases, in which 
continuous or near-continuous motor seizures impair hand and leg function anyway. (Bien 
et al., 2005b; Bien et al., 2009a; Terra-Bustamante et al., 2009; Terra-Bustamante et al., 2007) 
Regardless of the affected side, the probably least relevant consequence of surgery is 
hemianopia, which is usually well compensated in everyday life. In conclusion, especially in 
patients with impairing seizures and affection of the non-dominant hemisphere, surgery 
will often emerge as the superior long-term option compared to ongoing conservative 
treatment.(Bien et al., 2005b; Bien et al., 2009a; Terra-Bustamante et al., 2009; Terra-
Bustamante et al., 2007)  
9. Conclusions and future prospects 
Rasmussen’s encephalitis (RE) is a very rare disease of the brain, usually in children, 
characterized by focal seizures, ipsilateral cortical deficits and hemiparesis, as well as 
hemiatrophy of the contralateral cerebral hemisphere. Even though the European 
Consensus criteria has been proposed for its diagnosis, the aetio-pathogenesis remains 
enigmatic. 
The affected brain tissue shows a chronic T-cell mediated inflammatory histopathology and 
an autoimmune reaction is suspected.  Four groups of histopathological changes have been 
described with variable densities of microglial nodules, gyral necrosis, neuronal loss, glial 
scarring and gliosis. Following the natural history of the disease, three stages have been 
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proposed: the prodromal stage with a relatively low seizure frequency and mild hemiparesis; 
the acute stage with frequent seizures, and the residual stage. Focal epilepsy can be 
demonstrated by EEG while neuroimaging by CT scan or MRI demonstrates cerebral 
hemiatrophy. 
Anti-epileptic drugs have limited efficacy particularly in the control of EPC. Several 
immunomodulatory therapies have been tried. However being an orphan disease, no 
randomized clinical trials have demonstrated the long-term outcome of steroids, tacrolimus, 
plasmapharesis and immunoglobulin therapy. Whereas epileptic surgery is effective for 
seizure control, it is at the price of inducing severe neurological deficit.  
It is hoped that in the nearest future early diagnosis and extensive study of new cases in the 
prodromal phase may help unravel the antigenic stimulus for the T-cell-mediated response 
as well as the basis for the unilaterality of hemispheric damage. This may lead to specific 
immunotherapeutic techniques which can then be tested in multicenter randomized control 
trials.  
Better understanding of epilepsy therapeutics with combination of new and older 
antiepileptic drugs may result in better seizure control. (Owolabi et al., 2008) However, 
successes of non-surgical approaches have to be proven in the context of the natural 
evolution of the disease to a non-progressive phase. The decision to undergo surgery has to 
be individualized and predicated on the full information about the risks and benefits for the 
index patient. Novel and holistic approach to rehabilitation may result in improved quality 
of life for RE patients who can then march on to achieve their goals in life despite the fire of 
inflammation in the brain. 
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